NCT00290615View on ClinicalTrials.gov

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2011

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

bevacizumab

BIOLOGICAL

cetuximab

DRUG

capecitabine

DRUG

oxaliplatin

Trial Locations (2)

27710

Duke Comprehensive Cancer Center, Durham

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Hurwitz

OTHER

NCT00290615 - Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter